<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   IgA nephropathy: Recurrence after transplantation
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       IgA nephropathy: Recurrence after transplantation
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        IgA nephropathy: Recurrence after transplantation
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rowena Delos Santos, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Daniel C Brennan, MD, FACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John Vella, MD, FACP, FRCP, FASN, FAST
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Albert Q Lam, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jul 28, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Transplantation is the treatment of choice for individuals with progressive kidney failure due to IgA nephropathy (IgAN), which is caused by the deposition of IgA in the kidney parenchyma. Recurrent IgA deposition in the allograft is common and may cause hematuria, proteinuria, or progressive kidney dysfunction. Among some patients, however, IgA deposits are observed on biopsy but do not appear to cause clinically significant disease [
         <a href="#rid1">
          1
         </a>
         ]. IgA deposition may occur alone or be concurrent with other significant pathology, including chronic rejection.
        </p>
        <p>
         Issues related to recurrence after transplantation in patients with IgAN or IgA vasculitis (IgAV; Henoch-Schönlein purpura [HSP]) are reviewed here. Other aspects of IgAN and IgAV in the native kidney are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3095.html" rel="external">
          "IgA nephropathy: Pathogenesis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3112.html" rel="external">
          "IgA nephropathy: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3039.html" rel="external">
          "IgA nephropathy: Treatment and prognosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3107.html" rel="external">
          "IgA vasculitis (Henoch-Schönlein purpura): Kidney manifestations"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The reported frequency of histologic or clinically significant recurrence of IgAN varies in the reported literature, with the incidence probably increasing as a function of time from transplantation [
         <a href="#rid2">
          2-4
         </a>
         ]. In the multicenter Post-Transplant Glomerular Disease (TANGO) cohort study of 504 transplant recipients with biopsy-proven IgAN as the cause of end-stage kidney disease (ESKD) in the native kidneys, the cumulative incidence of recurrence was 19 percent at 10 years and 23 percent at 15 years [
         <a href="#rid5">
          5
         </a>
         ]. Among patients with recurrent IgAN, the median time to recurrence was 3.4 years.
        </p>
        <p>
         Histologic recurrence, with or without evidence of clinical disease, is common. As an example, in a combined retrospective and prospective study that reviewed biopsies from 29 allografts, histologic recurrence of IgA deposition was found in 17 patients (58 percent) [
         <a href="#rid6">
          6
         </a>
         ]. Three of these patients had a normal urinalysis and normal glomeruli on light microscopy, while five had hematuria, heavy proteinuria, hypertension, and progressive kidney failure due to IgAN alone. The only predictor for recurrence was a longer time after transplantation (46 versus 15 months in those without recurrence).
        </p>
        <p>
         In retrospective analyses of allograft biopsies obtained due to clinical concern for graft dysfunction, the recurrence of IgAN has ranged from 21 to 58 percent [
         <a href="#rid6">
          6-11
         </a>
         ].
        </p>
        <p>
         The prognosis of patients who develop recurrent IgAN is discussed below. (See
         <a class="local">
          'Prognosis'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H96090233">
         <span class="h1">
          RISK FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Possible risk factors for recurrence include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use of living-related-donor kidney
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Specific human leukocyte antigen (HLA) alleles in recipient including HLA-B35, HLA-DR4, HLA-B8, HLA-DR3
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Good HLA match between donor and recipient
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Glucocorticoid withdrawal
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         High serum IgA concentration
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Elevated galactose-deficient (Gd)-IgA1-specific immunoglobulin G (IgG) autoantibodies
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rare genetic variants in complement factor H-related protein 5 (CFHR5)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Recipient age
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Donor effect
         </span>
         <span class="headingEndMark">
          —
         </span>
         The risk of recurrence may be higher among recipients of living-related-donor kidneys, compared with deceased-donor kidneys. Therefore, the expected advantage in allograft survival with a living-related- compared with deceased-donor source may be negated. However, there is
         <strong>
          no
         </strong>
         basis for avoiding a living-related-donor source, largely due to the reported equivalence of graft survival independent of IgAN recurrence, but also given the expected deceased-donor waiting-list time and a reported decrease in patient mortality and increase in graft survival with earlier transplantation in relation to time on dialysis [
         <a href="#rid12">
          12-14
         </a>
         ].
        </p>
        <p>
         Conflicting data exist concerning a possible increased risk for recurrent IgAN in recipients of living, related allografts, compared with that with unrelated (living- or deceased-donor) allografts:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Several retrospective analyses have found no increased risk of recurrence based upon living- versus deceased-donor status [
         <a href="#rid9">
          9,10,15
         </a>
         ]. Another report found no difference in risk among recipients of living, related versus living, unrelated donors [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         By comparison, other studies have reported an increased risk of recurrence in recipients of living, related allografts [
         <a href="#rid16">
          16-19
         </a>
         ]. There was no significant difference in graft survival based upon donor status in some reports [
         <a href="#rid16">
          16,17
         </a>
         ], while others reported a survival advantage for living, related donors [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Human leukocyte antigen effect
         </span>
         <span class="headingEndMark">
          —
         </span>
         HLA specificity may affect the likelihood of recurrent IgAN, with the presence of either HLA-B35 or HLA-DR4 increasing the risk in some series [
         <a href="#rid21">
          21,22
         </a>
         ]. Other studies noted a higher representation of HLA-B35 and HLA-DR4 in the IgAN population, but their presence had no effect on the incidence of recurrence [
         <a href="#rid7">
          7,10,16,19,23,24
         </a>
         ]. An analysis of the Eurotransplant registry revealed that the 10-year graft survival was significantly lower among patients with IgAN and HLA-B8, DR3 than those with IgAN without HLA-B8, DR3 (52.5 percent versus 69.1 percent, respectively) [
         <a href="#rid25">
          25
         </a>
         ]. Graft survival was worse even among those with zero-mismatched kidneys, suggesting that graft loss may be due to factors other than rejection, although no definite association with IgAN recurrence was demonstrated. Conversely, the presence of HLA-B8, DR3 did not influence graft outcomes among control patients with pyelonephritis/interstitial nephritis and polycystic kidney disease (PKD).
        </p>
        <p>
         A separate issue is the importance of HLA matching:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a series of 54 patients with 61 kidney transplants for end-stage kidney disease (ESKD) due to IgAN, there was a statistically significant decrease in graft survival with
         <strong>
          better
         </strong>
         HLA-DR matching [
         <a href="#rid9">
          9,26
         </a>
         ]. There were insufficient numbers to separately calculate the effect in living-related- versus deceased-donor recipients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study of 86 kidney transplant recipients with a history of IgAN, the risk of IgAN recurrence was decreased among those who had an HLA-B full mismatch with their donor, compared with those who had at least a one HLA-B match [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A registry study of 1354 patients with end-stage disease due to IgAN from Australia and New Zealand showed that zero-HLA-mismatched living-donor recipients were more likely to develop recurrence (17 percent) than the whole cohort of living and deceased donors (7 percent) [
         <a href="#rid19">
          19
         </a>
         ]. In addition, although graft survival did not differ among those with recurrence and zero HLA mismatches compared with one or more HLA mismatches, the survival advantage of zero-antigen HLA mismatches compared with one or more HLA mismatches was lost.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Conversely, a Korean study found no association with full HLA match and the risk of recurrent IgAN among patients with IgAN [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2191323510">
         <span class="h2">
          Glucocorticoid withdrawal
         </span>
         <span class="headingEndMark">
          —
         </span>
         Early withdrawal of glucocorticoids from the maintenance immunosuppression regimen after kidney transplantation may be associated with an increased risk of recurrent IgAN. In a retrospective study of 9690 transplant recipients (2831 with early glucocorticoid withdrawal and 6859 with continued glucocorticoid use), 1238 patients experienced graft loss; 15.4 percent of these cases were due to IgAN recurrence [
         <a href="#rid28">
          28
         </a>
         ]. A multivariate analysis found that continued glucocorticoid use was associated with a decreased risk of recurrence (hazard ratio [HR] 0.67, 95% CI 0.48 to 0.92). Patient survival and death-censored graft survival did not differ between the two groups. Similar findings were shown in another study that evaluated the impact of immunosuppressive therapy on the risk of recurrent IgAN among 120 transplant recipients with IgAN of the native kidney [
         <a href="#rid29">
          29
         </a>
         ]. IgAN recurrence occurred in 28 of 51 allografts (55 percent) that were biopsied posttransplant. Although the use of maintenance immunosuppressive medications was not associated with an increased risk for IgAN recurrence, there was a nearly eightfold higher risk of IgAN recurrence among patients who experienced glucocorticoid withdrawal at any time posttransplant.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Serum IgA concentration
         </span>
         <span class="headingEndMark">
          —
         </span>
         An increased serum IgA concentration may be a risk factor for recurrence [
         <a href="#rid18">
          18,30
         </a>
         ]. This was suggested by a retrospective analysis of 48 transplant recipients who had biopsy-proven IgAN as a cause of ESKD of the native kidney [
         <a href="#rid18">
          18
         </a>
         ]. The mean IgA value was higher among 14 patients with recurrence, compared with 34 patients without recurrence (4 versus 3.25 g/L, respectively).
        </p>
        <p class="headingAnchor" id="H2690313640">
         <span class="h2">
          Galactose-deficient IgA1-specific IgG autoantibodies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Elevated serum levels of Gd-IgA1-specific IgG autoantibody at the time of transplant may be associated with a higher risk of recurrence. In one study of 96 kidney transplant recipients with native kidney IgAN, an elevated level of normalized serum Gd-IgA1-specific IgG autoantibodies at the time of transplant was an independent risk factor for recurrent IgAN (relative risk 2.96, 95% CI 1.31-6.70) [
         <a href="#rid31">
          31
         </a>
         ]. However, the same autoantibody level was not predictive of allograft failure. Further studies to validate these findings are needed.
        </p>
        <p class="headingAnchor" id="H3281284455">
         <span class="h2">
          Rare genetic variants in CFHR5
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is increasing evidence supporting a role for complement dysregulation in the pathogenesis of IgAN (see
         <a class="medical medical_review" href="/z/d/html/3095.html" rel="external">
          "IgA nephropathy: Pathogenesis", section on 'Complement activation'
         </a>
         ). Genome-wide association studies (GWAS) have identified abnormalities in the complement factor H (CFH) and the CFH-related (CFHR) genes in patients with IgAN [
         <a href="#rid32">
          32,33
         </a>
         ]. In particular, rare genetic variants in the CFHR protein 5 (CFHR5) gene have been associated with an increased genetic susceptibility to IgAN [
         <a href="#rid34">
          34
         </a>
         ]. However, it is unclear if any of these CFHR5 variants increase the risk of IgAN recurrence posttransplant.
        </p>
        <p class="headingAnchor" id="H3478773736">
         <span class="h2">
          Recipient age
         </span>
         <span class="headingEndMark">
          —
         </span>
         Age may be a risk factor for IgAN recurrence posttransplantation. In a study of 86 transplant recipients with a history of IgAN, younger age at the time of transplantation was a risk factor for disease recurrence and eventual development of allograft dysfunction [
         <a href="#rid27">
          27
         </a>
         ]. The risk of IgAN recurrence decreased as a function of age at the time of transplant.
        </p>
        <p class="headingAnchor" id="H96093778">
         <span class="h1">
          PREVENTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no known preventive therapy for IgAN recurrence. Among transplant recipients, there are no conclusive data that the selection of immunosuppressive therapy alters the risk of recurrence (other than glucocorticoid withdrawal). No significant difference, for example, has been observed in the incidence or severity of IgAN in studies comparing the pre- and post-cyclosporine eras [
         <a href="#rid8">
          8,9
         </a>
         ]. There is some evidence that the use of
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil may decrease the risk of IgAN recurrence in the short term [
         <a href="#rid7">
          7,35,36
         </a>
         ]. However, other studies have found no association with mycophenolate and recurrent IgAN [
         <a href="#rid37">
          37-39
         </a>
         ]. Furthermore, in an analysis of the United States Renal Data System, the use of mycophenolate was associated with a nonsignificant trend towards an increased risk of graft loss due to recurrent IgAN (hazard ratio [HR] 1.79, 95% CI 0.49-6.49) [
         <a href="#rid40">
          40
         </a>
         ]. In this same study, a nonsignificant trend for a decreased risk of graft loss due to recurrent IgAN was associated with the use of steroids (HR 0.57, 95% CI 0.12-2.71). However, neither association reached statistical significance. In an analysis of the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) of 1521 first-time kidney transplant recipients with end-stage kidney disease (ESKD) from IgA, maintenance steroid use was strongly associated with a reduced risk of recurrence (subhazard ratio 0.50, 95% CI 0.30–0.84) after adjusting for age, sex, human leukocyte antigen (HLA) mismatch, dialysis duration, and transplant era [
         <a href="#rid41">
          41
         </a>
         ]. Limited data showed that kidney transplant patients who used
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         had less recurrence [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
         Whether the choice of induction agent has any beneficial clinical effect on the incidence of recurrent IgAN is unclear. A retrospective analysis reported that the prevalence of recurrent IgA following transplantation was significantly reduced in patients receiving antithymocyte globulin, compared with either interleukin-2 (IL-2) induction or no induction treatment [
         <a href="#rid42">
          42
         </a>
         ]. In this report, the 10-year cumulative recurrence rate, as defined by clinically directed biopsy, was 36 percent overall, 9 percent with antithymocyte induction, 41 percent with no induction, and 41 percent at a shorter five-year follow-up with IL-2 induction. Maintenance immunosuppression varied with the era. Graft loss from recurrent IgAN was 6 percent overall, and there was no difference in overall graft or patient survival based on choice of induction agent. Another study found a reduced risk of recurrent glomerulonephritis with antithymocyte globulin induction, compared with either IL-2 or
         <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">
          alemtuzumab
         </a>
         induction (HR 0.13, 95% CI 0.02-0.98) [
         <a href="#rid43">
          43
         </a>
         ]. Among persons with IgAN, recurrent disease occurred in 0, 7.3, and 3.7 percent with antithymocyte globulin, IL-2, and alemtuzumab induction, respectively.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with recurrent IgA generally present with persistent microscopic hematuria. New or worsening proteinuria or, occasionally, an increase in the serum creatinine may also be seen. In one study that included 42 patients with recurrent IgAN, the following clinical presentations were observed [
         <a href="#rid11">
          11
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Isolated microscopic hematuria (5 patients)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Isolated proteinuria (8 patients)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Microscopic hematuria plus proteinuria (12 patients)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Isolated increase in serum creatinine (4 patients)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased creatinine with either hematuria or proteinuria (13 patients)
        </p>
        <p>
        </p>
        <p>
         If IgAN recurs, the time to onset of clinical manifestations due to kidney IgA deposition varies. In one study of 61 transplant recipients with initial kidney loss due to IgAN (of whom 18 had recurrent disease), the mean time to clinical recurrence and allograft failure was 31 and 63 months, respectively [
         <a href="#rid9">
          9
         </a>
         ]. Occasionally, patients may develop early graft failure associated with crescentic IgAN [
         <a href="#rid21">
          21,44,45
         </a>
         ].
        </p>
        <p>
         Patients who had a rapidly progressive course to end-stage kidney disease (ESKD) in the native kidney tend to present early after transplantation with clinically significant recurrence [
         <a href="#rid9">
          9,10,16,46
         </a>
         ]. Thus, patients with a rapidly progressive course of IgAN in their native kidneys should be informed that recurrent disease in the transplanted kidney may manifest early.
        </p>
        <p>
         Similarly, patients with early graft loss from recurrent IgAN may have rapid recurrence of clinically significant disease following repeat transplantation; however, this is not certain, and good long-term outcomes have been described among such patients. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
         While persistent microscopic hematuria in a patient with IgAN is likely secondary to recurrent disease, this should not be assumed, and other potential etiologies should be investigated.
        </p>
        <p class="headingAnchor" id="H96093912">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Recurrent IgAN should be suspected among patients who have a history of IgAN and who present with hematuria, new or worsening proteinuria, or an increased creatinine. The diagnosis is made by biopsy. The indications for biopsy vary among clinicians. All agree that, among transplant recipients with a history of IgAN, the following are indications for a transplant biopsy:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An elevated creatinine above baseline, and/or
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Significant proteinuria (defined as &gt;500 mg/day) despite an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB), and/or
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Persistent hematuria in the setting of a negative urologic evaluation
        </p>
        <p>
        </p>
        <p>
         Some clinicians would also biopsy patients who present with isolated, persistent, low-grade proteinuria (defined as &lt;500 mg/day), regardless of the absence or presence of an ACEI or ARB, whereas others would not perform a biopsy for such patients, providing the creatinine remained stable.
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest that all patients with recurrent IgAN be treated with an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB). Treatment with an ACEI or ARB may delay progression of recurrent disease in allografts [
         <a href="#rid47">
          47,48
         </a>
         ].
        </p>
        <p>
         We suggest that patients who had IgAN of the native kidneys, but who have no evidence of recurrence and do not have hypertension, not be treated with ACEI or ARB. It is not known whether early posttransplant initiation of these agents to all recipients with native IgAN, independent of disease recurrence, is beneficial.
        </p>
        <p>
         Most studies that examined the benefit of ACEI therapy among patients with IgAN have included only nontransplant patients. These studies are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3039.html" rel="external">
          "IgA nephropathy: Treatment and prognosis", section on 'Angiotensin inhibition'
         </a>
         .)
        </p>
        <p>
         There are limited data on the benefit of ACEIs or ARBs among transplant recipients [
         <a href="#rid47">
          47,48
         </a>
         ]. The best data are from a retrospective review of 75 transplant recipients with known IgAN of the native kidney, which demonstrated a higher 5- and 10-year graft survival associated with the use of ACEIs or ARBs, but this was not statistically significant [
         <a href="#rid48">
          48
         </a>
         ]. Among patients with biopsy-proven recurrence, of those on an ACEI or ARB, three of nine progressed to end-stage kidney disease (ESKD). Among four patients with biopsy-proven IgAN who were not being treated with an ACEI or ARB, all progressed to ESKD.
        </p>
        <p>
         It is not clear that graft survival is actually improved by initiating either an ACEI or an ARB following the detection of recurrent IgAN [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
         There have also been case reports of fish oil having a favorable effect in recurrent IgAN, but no studies have been performed to support its routine use [
         <a href="#rid49">
          49
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3039.html" rel="external">
          "IgA nephropathy: Treatment and prognosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7169.html" rel="external">
          "Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults"
         </a>
         .)
        </p>
        <p>
         Immunosuppressive therapy specifically directed toward treatment of recurrent IgAN may be indicated in selected patients, such as those with biopsy-proven recurrence and rapidly rising serum creatinine or nephrotic-range proteinuria despite the use of ACEIs or ARBs. The optimal immunosuppressive therapy for recurrent IgAN is not known, and the approach is derived from studies of IgAN in the native kidney. (See
         <a class="medical medical_review" href="/z/d/html/3039.html" rel="external">
          "IgA nephropathy: Treatment and prognosis", section on 'Immunosuppressive therapy in high-risk patients'
         </a>
         .)
        </p>
        <p>
         Among such patients, high-dose glucocorticoids (such as
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         1 mg/kg/day) may be given for two months, followed by a slow taper back to low doses commonly used to prevent rejection.
        </p>
        <p>
         An oral targeted-release formulation of the glucocorticoid
         <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">
          budesonide
         </a>
         (TRF-budesonide), which is designed to provide controlled release of budesonide in areas of the gut that have a high density of Peyer patches, has been shown to reduce proteinuria in nontransplant patients with IgAN of the native kidneys [
         <a href="#rid50">
          50
         </a>
         ]. However, a similar benefit was not observed in a small series of transplant recipients who received a different formulation of targeted-release budesonide (which provided controlled release of budesonide throughout the colon) for recurrent IgAN [
         <a href="#rid51">
          51
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3039.html" rel="external">
          "IgA nephropathy: Treatment and prognosis", section on 'Other regimens'
         </a>
         .)
        </p>
        <p>
         Patients who have a rapidly increasing serum creatinine despite high-dose glucocorticoids may benefit from oral or intravenous
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         , based upon studies of patients with IgAN in the native kidney. There are no studies of these agents among patients with recurrent IgAN. (See
         <a class="medical medical_review" href="/z/d/html/3039.html" rel="external">
          "IgA nephropathy: Treatment and prognosis", section on 'Angiotensin inhibition'
         </a>
         .)
        </p>
        <p>
         If
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         is used, the current antimetabolite used to prevent rejection (usually
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil or
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         ) should be discontinued for the duration that the patient is on cyclophosphamide to mitigate the risk of severe myelosuppression.
        </p>
        <p>
         The use of
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         in the treatment or prevention of recurrent IgAN has not been studied. However, a randomized controlled trial of nontransplant patients with IgAN that compared rituximab plus supportive therapy with supportive therapy alone found no benefit [
         <a href="#rid52">
          52
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3039.html" rel="external">
          "IgA nephropathy: Treatment and prognosis", section on 'Other regimens'
         </a>
         .)
        </p>
        <p>
         Some data suggest that tonsillectomy may improve histologic and clinical findings of recurrent IgAN [
         <a href="#rid53">
          53,54
         </a>
         ]. However, pretransplant tonsillectomy in patients with IgAN does not appear to prevent disease recurrence [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H96089893">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Given the lack of a prospective study involving protocol biopsies, the true risk of significant graft dysfunction and/or graft loss from recurrent disease is unclear [
         <a href="#rid6">
          6-11,16,56
         </a>
         ].
        </p>
        <p>
         Historically, it was thought that, despite the risk of recurrent disease, among patients with a history of IgAN, the overall graft survival was similar to that of patients with a history of non-IgA glomerular or nonglomerular disease. As an example, in a large retrospective analysis (532 allograft recipients with primary IgAN) from Australia, the estimated 10-year incidence of graft loss due to recurrent disease was 9.7 percent [
         <a href="#rid56">
          56
         </a>
         ]. Allografts in IgAN recipients exhibited a similar 10-year survival as allografts in recipients with either non-IgA glomerular or nonglomerular disease. In this series, recurrent IgAN was a less frequent cause of graft loss than either chronic rejection or death with a functioning graft. The risk of graft loss in relation to donor source was not evaluated.
        </p>
        <p>
         However, other data provide further information on the long-term allograft survival of patients with IgAN. One study found that in patients with IgAN as the etiology for end-stage kidney disease (ESKD), IgAN recurrence posttransplantation was associated with allograft failure; the median time from diagnosis of recurrent IgAN to allograft loss was 3.1 years [
         <a href="#rid57">
          57
         </a>
         ]. Another group reported that allograft survival beyond 12 years was lower for patients with IgAN compared with non-IgAN patients [
         <a href="#rid58">
          58
         </a>
         ]. A third study that examined 15-year outcomes reported that death-censored graft survival was lower among patients with recurrent IgAN compared with controls (62.6 versus 72.4 percent, respectively) [
         <a href="#rid11">
          11
         </a>
         ]. In the Post-Transplant Glomerular Disease (TANGO) study, the risk of graft loss was higher among patients with recurrence of IgAN than among those who did not have recurrence (hazard ratio 3.69, 95% CI 2.04-6.66) [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         Recurrent IgAN in combination with chronic rejection has a worse prognosis, compared with recurrent IgAN alone [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p>
         There are only a few studies that have examined outcomes of a second transplant after the first was lost to recurrent IgAN. However, good long-term function has been described, despite evidence of IgA deposition in the second allograft [
         <a href="#rid9">
          9,46
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H96090738">
         <span class="h2">
          Markers for progression
         </span>
         <span class="headingEndMark">
          —
         </span>
         As with all glomerulopathies, increased urinary protein excretion and increased sclerosis and fibrosis on kidney biopsy with IgAN are associated with an enhanced risk of progressive disease. In one study of recurrent IgAN, for example, urine protein excretion &gt;1 g/day and biopsy findings of prominent glomerulosclerosis (involving &gt;30 percent of glomeruli) were associated with universal graft loss by six years after transplantation [
         <a href="#rid60">
          60
         </a>
         ]. By comparison, urinary excretion &lt;1 g/day and a kidney biopsy in which &lt;10 percent of glomeruli show glomerulosclerosis forecast stable allograft function at nine years posttransplantation. In another study, the presence of glomerular crescents correlated with worse allograft survival [
         <a href="#rid57">
          57
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7181.html" rel="external">
          "Secondary factors and progression of chronic kidney disease"
         </a>
         .)
        </p>
        <p>
         The Oxford classification of IgAN, which is used to score kidney biopsies on the basis of five histologic variables (mesangial hypercellularity [M], endocapillary hypercellularity [E], segmental glomerulosclerosis [S], tubular atrophy/interstitial fibrosis [T], and crescents [C]), has been shown to predict kidney outcomes in nontransplant patients with IgAN. Studies suggest that the Oxford classification also has prognostic value in transplant recipients with recurrent IgAN, with higher MEST-C scores being associated with graft failure [
         <a href="#rid61">
          61-63
         </a>
         ]. The Oxford classification is discussed in greater detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3112.html" rel="external">
          "IgA nephropathy: Clinical features and diagnosis", section on 'Oxford classification of IgAN'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3039.html" rel="external">
          "IgA nephropathy: Treatment and prognosis", section on 'Risk factors for disease progression'
         </a>
         .)
        </p>
        <p>
         Although persistent microscopic hematuria may be an early marker of recurrent IgAN, its onset does not necessarily predict a poor outcome. A review of 41 kidney transplant recipients with primary IgAN found a higher prevalence of persistent microscopic hematuria, compared with recipients with other native kidney disease (32 versus 12 percent, respectively) [
         <a href="#rid64">
          64
         </a>
         ]. Hematuria in the IgAN patients was not associated with donor status, kidney function, or time since transplantation.
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          IgA VASCULITIS (HENOCH-SCHÖNLEIN PURPURA)
         </span>
         <span class="headingEndMark">
          —
         </span>
         IgA vasculitis (IgAV; Henoch-Schönlein purpura [HSP]), which has kidney manifestations indistinguishable from IgAN, usually occurs in children, but has also been reported in adults. (See
         <a class="medical medical_review" href="/z/d/html/3107.html" rel="external">
          "IgA vasculitis (Henoch-Schönlein purpura): Kidney manifestations"
         </a>
         .)
        </p>
        <p>
         The risk of recurrence of IgAV (HSP) appears to be the same as for IgAN, although data are limited. One analysis found overall a recurrence rate of 15 percent and graft survival rates of nearly 90 percent at 10 years, while another pooled analysis demonstrated clinically significant disease in 35 percent and graft loss in 11 percent at five years posttransplantation [
         <a href="#rid65">
          65,66
         </a>
         ]. Also similar to IgAN, patients with a rapid pretransplant course culminating in kidney failure tended to develop prompt recurrence in the allograft.
        </p>
        <p>
         Another study evaluated 13 patients who collectively received 18 kidney transplants and underwent protocol biopsies at the time of implantation, 3 months, and 12 months posttransplant, as well as biopsies for allograft dysfunction and proteinuria [
         <a href="#rid67">
          67
         </a>
         ]. Histologic recurrence of IgAV (HSP) occurred in 11 of 18 (61 percent) allografts at a mean follow-up of 83 months. Only one patient presented with evidence of clinical disease. No patient in this study experienced allograft loss due to IgAV (HSP) recurrence [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          OTHER CAUSES OF GLOMERULAR IgA DEPOSITION
         </span>
         <span class="headingEndMark">
          —
         </span>
         IgA deposition that is unrelated to recurrent disease in a kidney allograft is not uncommon [
         <a href="#rid68">
          68
         </a>
         ]. Kidney allograft recipients without native IgAN but with cirrhosis or celiac disease (gluten enteropathy) may develop mesangial IgA deposits [
         <a href="#rid69">
          69,70
         </a>
         ]. Impaired removal of IgA complexes in liver disease [
         <a href="#rid71">
          71,72
         </a>
         ] and the formation of IgA anti-gluten antibodies in celiac disease [
         <a href="#rid73">
          73
         </a>
         ] are thought to underlie this process. (See
         <a class="medical medical_review" href="/z/d/html/3112.html" rel="external">
          "IgA nephropathy: Clinical features and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4774.html" rel="external">
          "Epidemiology, pathogenesis, and clinical manifestations of celiac disease in adults"
         </a>
         .)
        </p>
        <p>
         Despite the IgA deposition, it is unusual for clinical evidence of kidney disease related to IgAN to be apparent in a native (or transplant) kidney in this setting [
         <a href="#rid69">
          69,70
         </a>
         ]. The absence of clinically significant disease is postulated to result from a lack of complement activation and resultant inflammatory response [
         <a href="#rid70">
          70
         </a>
         ]. The degree of concurrent IgG and complement deposition on immunofluorescence may help clarify whether the mesangial IgA deposition is solely a histologic finding or relevant to graft dysfunction.
        </p>
        <p>
         Among patients with liver disease and progressive IgAN, the nephropathy may resolve after liver transplantation [
         <a href="#rid74">
          74
         </a>
         ]. Similarly, in a native kidney with celiac disease-induced IgAN, the nephropathy may resolve with a gluten-free diet [
         <a href="#rid75">
          75,76
         </a>
         ].
        </p>
        <p>
         There are no published data looking at the potential recurrence of IgAN in kidney transplant recipients in association with celiac disease. Although it would be rare for a patient to have graft dysfunction as a result of IgA deposition in this setting, given the incidence of celiac disease in the general population, particularly in diabetics, it is reasonable to screen patients with recurrent IgAN for celiac disease, especially those with otherwise unexplained diarrhea, malabsorption, or iron deficiency. (See
         <a class="medical medical_review" href="/z/d/html/4771.html" rel="external">
          "Diagnosis of celiac disease in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          TRANSPLANTATION OF A KIDNEY WITH IgA DEPOSITS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both deceased- and living-donor kidneys with IgA deposition have been transplanted into non-IgAN recipients. In one study of 70 living-donor kidney biopsies obtained just prior to transplantation, 13 percent had glomerular IgA deposits [
         <a href="#rid77">
          77
         </a>
         ]. Another report described the presence of latent mesangial IgA deposits in approximately 16 percent of biopsies obtained at the time of transplantation from both living and deceased donors otherwise considered healthy [
         <a href="#rid78">
          78
         </a>
         ]. Graft outcomes were not reported in either of these analyses.
        </p>
        <p>
         A prospective analysis of 83 recipients of deceased-donor allografts with IgA deposition reported an increased incidence of early acute rejection (31 versus 19 percent), delayed graft function, proteinuria, and hematuria, compared with 259 recipients of a deceased-donor allograft without evidence of IgA deposition [
         <a href="#rid79">
          79
         </a>
         ]. Serial protocol biopsies tended to demonstrate gradual resolution of IgA deposition within 45 days following transplantation, as well as resolution of the proteinuria and hematuria. Despite the increased incidence of acute rejection and clinical signs of allograft dysfunction, graft survival at one and three years was similar in both groups.
        </p>
        <p>
         Two other series with a total of 12 patients noted rapid resolution of IgA deposits after transplantation in most patients [
         <a href="#rid80">
          80,81
         </a>
         ]. At present, our practice is
         <strong>
          not
         </strong>
         to use kidneys with known IgA deposits for donation. However, we have unknowingly transplanted deceased-donor allografts with evidence of IgA deposition evident on an early posttransplant biopsy that has resolved on follow-up biopsy with no evidence for adverse outcome on graft function or survival.
        </p>
        <p class="headingAnchor" id="H808367987">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110754.html" rel="external">
          "Society guideline links: Kidney transplantation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations
         </strong>
         – IgA nephropathy (IgAN) is caused by the deposition of IgA in the kidney parenchyma. IgAN may cause progressive kidney dysfunction. Transplantation is the treatment of choice for individuals with progressive kidney failure. Recurrent IgA deposition in the allograft is common and may cause hematuria, proteinuria, or progressive kidney dysfunction. Among some patients, however, IgA deposits are observed on biopsy, but do not appear to cause clinically significant disease. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk factors
         </strong>
         – The risk of recurrence may be higher among recipients of living-related-donor kidneys, compared with deceased-donor kidneys. However, there is
         <strong>
          no
         </strong>
         basis for avoiding a living-related-donor source, largely due to the reported equivalence of graft survival independent of IgAN recurrence, but also given the expected deceased-donor waiting-list time and a reported decrease in patient mortality and increase in graft survival with earlier transplantation in relation to time on dialysis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other possible risk factors for recurrence include glucocorticoid withdrawal, specific human leukocyte antigen (HLA) alleles among recipients, a close HLA match between donor and recipient, increased serum IgA concentrations among recipients, serum levels of galactose-deficient IgA1-specific IgG autoantibodies, and rare genetic variants in complement factor H-related protein 5. However, none of these risk factors have been validated. (See
         <a class="local">
          'Risk factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of recurrent IgAN is made by biopsy. Indications for a transplant biopsy include an elevated creatinine above baseline and/or significant proteinuria (defined as &gt;500 mg/day) despite an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) and/or persistent hematuria in the setting of a negative urologic evaluation. Some clinicians would also biopsy patients who present with isolated, persistent, low-grade proteinuria (defined as &lt;500 mg/day), regardless of the absence or presence of an ACEI or ARB, whereas others would not perform a biopsy for such patients, providing the creatinine remained stable. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention
         </strong>
         – There is no known preventive therapy for IgAN recurrence. There are no conclusive data that the selection of immunosuppressive therapy alters the risk of recurrence. (See
         <a class="local">
          'Prevention'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Generally, all patients with recurrent IgAN are treated with ACEIs or ARBs, which may delay progression of recurrent disease in allografts. Patients with IgAN of the native kidney and hypertension are treated with an ACEI or ARB, even in the absence of any evidence of recurrent disease, although patients who had IgAN of the native kidney, but who have no evidence of recurrence and do not have hypertension, are generally not treated with ACEIs or ARBs. It is not known whether early posttransplant initiation of these agents to all recipients with native IgAN, independent of disease recurrence, is beneficial.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Immunosuppressive therapy specifically directed toward treatment of recurrent IgA may be used in selected patients, such as those with biopsy-proven recurrence and rapidly rising serum creatinine or nephrotic-range proteinuria despite the use of ACEIs or ARBs. Among such patients, high-dose glucocorticoids may be given for two months, followed by a slow taper back to low doses commonly used to prevent rejection. Patients who have a rapidly increasing serum creatinine despite high-dose glucocorticoids may benefit from oral or intravenous
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         , based upon studies of patients with IgAN in the native kidney. If cyclophosphamide is used, the current antimetabolite used to prevent rejection (usually
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil or
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         ) should be discontinued for the duration that the patient is on cyclophosphamide. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – Overall, the reported risk of graft loss due to recurrent disease is approximately 7 to 10 percent at 10 years, but the risk is probably higher than this as time from transplant increases. Among patients with graft dysfunction attributed to recurrent IgAN, the risk of graft loss is much higher. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H346556276">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Georges Saab, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Kowalewska J, Yuan S, Sustento-Reodica N, et al. IgA nephropathy with crescents in kidney transplant recipients. Am J Kidney Dis 2005; 45:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andresdottir MB, Haasnoot GW, Doxiadis II, et al. Exclusive characteristics of graft survival and risk factors in recipients with immunoglobulin A nephropathy: a retrospective analysis of registry data. Transplantation 2005; 80:1012.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koch MJ. Considerations in retransplantation of the failed renal allograft recipient. Adv Chronic Kidney Dis 2006; 13:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choy BY, Chan TM, Lai KN. Recurrent glomerulonephritis after kidney transplantation. Am J Transplant 2006; 6:2535.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uffing A, Pérez-Saéz MJ, Jouve T, et al. Recurrence of IgA Nephropathy after Kidney Transplantation in Adults. Clin J Am Soc Nephrol 2021; 16:1247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Odum J, Peh CA, Clarkson AR, et al. Recurrent mesangial IgA nephritis following renal transplantation. Nephrol Dial Transplant 1994; 9:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim YS, Moon JI, Jeong HJ, et al. Live donor renal allograft in end-stage renal failure patients from immunoglobulin A nephropathy. Transplantation 2001; 71:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kessler M, Hiesse C, Hestin D, et al. Recurrence of immunoglobulin A nephropathy after renal transplantation in the cyclosporine era. Am J Kidney Dis 1996; 28:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bumgardner GL, Amend WC, Ascher NL, Vincenti FG. Single-center long-term results of renal transplantation for IgA nephropathy. Transplantation 1998; 65:1053.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frohnert PP, Donadio JV Jr, Velosa JA, et al. The fate of renal transplants in patients with IgA nephropathy. Clin Transplant 1997; 11:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moroni G, Longhi S, Quaglini S, et al. The long-term outcome of renal transplantation of IgA nephropathy and the impact of recurrence on graft survival. Nephrol Dial Transplant 2013; 28:1305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kasiske BL, Snyder JJ, Matas AJ, et al. Preemptive kidney transplantation: the advantage and the advantaged. J Am Soc Nephrol 2002; 13:1358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mange KC, Joffe MM, Feldman HI. Effect of the use or nonuse of long-term dialysis on the subsequent survival of renal transplants from living donors. N Engl J Med 2001; 344:726.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meier-Kriesche HU, Kaplan B. Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes: a paired donor kidney analysis. Transplantation 2002; 74:1377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ponticelli C, Traversi L, Feliciani A, et al. Kidney transplantation in patients with IgA mesangial glomerulonephritis. Kidney Int 2001; 60:1948.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freese P, Svalander C, Nordén G, Nyberg G. Clinical risk factors for recurrence of IgA nephropathy. Clin Transplant 1999; 13:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andresdottir MB, Hoitsma AJ, Assmann KJ, Wetzels JF. Favorable outcome of renal transplantation in patients with IgA nephropathy. Clin Nephrol 2001; 56:279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang AY, Lai FM, Yu AW, et al. Recurrent IgA nephropathy in renal transplant allografts. Am J Kidney Dis 2001; 38:588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDonald SP, Russ GR. Recurrence of IgA nephropathy among renal allograft recipients from living donors is greater among those with zero HLA mismatches. Transplantation 2006; 82:759.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Han SS, Huh W, Park SK, et al. Impact of recurrent disease and chronic allograft nephropathy on the long-term allograft outcome in patients with IgA nephropathy. Transpl Int 2010; 23:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brensilver JM, Mallat S, Scholes J, McCabe R. Recurrent IgA nephropathy in living-related donor transplantation: recurrence or transmission of familial disease? Am J Kidney Dis 1988; 12:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matsugami K, Naito T, Nitta K, et al. [A clinicopathological study of recurrent IgA nephropathy following renal transplantation]. Nihon Jinzo Gakkai Shi 1998; 40:322.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hiki Y, Kobayashi Y, Ookubo M, et al. Association of HLA-DQw4 with IgA nephropathy in the Japanese population. Nephron 1991; 58:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hiki Y, Kobayashi Y, Ookubo M, Kashiwagi N. The role of HLA-DR4 in the long-term prognosis of IgA nephropathy. Nephron 1990; 54:264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andresdottir MB, Haasnoot GW, Persijn GG, Claas FH. HLA-B8, DR3: a new risk factor for graft failure after renal transplantation in patients with underlying immunoglobulin A nephropathy. Clin Transplant 2009; 23:660.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ortiz F, Gelpi R, Koskinen P, et al. IgA nephropathy recurs early in the graft when assessed by protocol biopsy. Nephrol Dial Transplant 2012; 27:2553.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodas LM, Ruiz-Ortiz E, Garcia-Herrera A, et al. IgA Nephropathy Recurrence after Kidney Transplantation: Role of Recipient Age and Human Leukocyte Antigen-B Mismatch. Am J Nephrol 2020; 51:357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leeaphorn N, Garg N, Khankin EV, et al. Recurrence of IgA nephropathy after kidney transplantation in steroid continuation versus early steroid-withdrawal regimens: a retrospective analysis of the UNOS/OPTN database. Transpl Int 2018; 31:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Di Vico MC, Messina M, Fop F, et al. Recurrent IgA nephropathy after renal transplantation and steroid withdrawal. Clin Transplant 2018; 32:e13207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berger J. Recurrence of IgA nephropathy in renal allografts. Am J Kidney Dis 1988; 12:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berthoux F, Suzuki H, Mohey H, et al. Prognostic Value of Serum Biomarkers of Autoimmunity for Recurrence of IgA Nephropathy after Kidney Transplantation. J Am Soc Nephrol 2017; 28:1943.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gharavi AG, Kiryluk K, Choi M, et al. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet 2011; 43:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kiryluk K, Li Y, Scolari F, et al. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet 2014; 46:1187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhai YL, Meng SJ, Zhu L, et al. Rare Variants in the Complement Factor H-Related Protein 5 Gene Contribute to Genetic Susceptibility to IgA Nephropathy. J Am Soc Nephrol 2016; 27:2894.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nowack R, Birck R, van der Woude FJ. Mycophenolate mofetil for systemic vasculitis and IgA nephropathy. Lancet 1997; 349:774.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hauser IA, Renders L, Radeke HH, et al. Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion. Nephrol Dial Transplant 1999; 14:58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vongwiwatana A, Gourishankar S, Campbell PM, et al. Peritubular capillary changes and C4d deposits are associated with transplant glomerulopathy but not IgA nephropathy. Am J Transplant 2004; 4:124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chandrakantan A, Ratanapanichkich P, Said M, et al. Recurrent IgA nephropathy after renal transplantation despite immunosuppressive regimens with mycophenolate mofetil. Nephrol Dial Transplant 2005; 20:1214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pham PT, Pham PC. The impact of mycophenolate mofetil versus azathioprine as adjunctive therapy to cyclosporine on the rates of renal allograft loss due to glomerular disease recurrence. Nephrol Dial Transplant 2012; 27:2965.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mulay AV, van Walraven C, Knoll GA. Impact of immunosuppressive medication on the risk of renal allograft failure due to recurrent glomerulonephritis. Am J Transplant 2009; 9:804.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clayton P, McDonald S, Chadban S. Steroids and recurrent IgA nephropathy after kidney transplantation. Am J Transplant 2011; 11:1645.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berthoux F, El Deeb S, Mariat C, et al. Antithymocyte globulin (ATG) induction therapy and disease recurrence in renal transplant recipients with primary IgA nephropathy. Transplantation 2008; 85:1505.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pascual J, Mezrich JD, Djamali A, et al. Alemtuzumab induction and recurrence of glomerular disease after kidney transplantation. Transplantation 2007; 83:1429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Díaz-Tejeiro R, Maduell F, Diez J, et al. Loss of renal graft due to recurrent IgA nephropathy with rapidly progressive course: an unusual clinical evolution. Nephron 1990; 54:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Streather CP, Scoble JE. Recurrent IgA nephropathy in a renal allograft presenting as crescentic glomerulonephritis. Nephron 1994; 66:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ohmacht C, Kliem V, Burg M, et al. Recurrent immunoglobulin A nephropathy after renal transplantation: a significant contributor to graft loss. Transplantation 1997; 64:1493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oka K, Imai E, Moriyama T, et al. A clinicopathological study of IgA nephropathy in renal transplant recipients: beneficial effect of angiotensin-converting enzyme inhibitor. Nephrol Dial Transplant 2000; 15:689.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Courtney AE, McNamee PT, Nelson WE, Maxwell AP. Does angiotensin blockade influence graft outcome in renal transplant recipients with IgA nephropathy? Nephrol Dial Transplant 2006; 21:3550.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ng R. Fish oil therapy in recurrent IgA nephropathy. Ann Intern Med 2003; 138:1011.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barratt J, Lafayette R, Kristensen J, et al. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int 2023; 103:391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gandolfini I, Alibrandi S, Gentile M, et al. Targeted-release budesonide in recurrent IgA nephropathy after kidney transplantation. Kidney Int 2023; 103:995.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lafayette RA, Canetta PA, Rovin BH, et al. A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction. J Am Soc Nephrol 2017; 28:1306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hotta K, Fukasawa Y, Akimoto M, et al. Tonsillectomy ameliorates histological damage of recurrent immunoglobulin A nephropathy after kidney transplantation. Nephrology (Carlton) 2013; 18:808.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kennoki T, Ishida H, Yamaguchi Y, Tanabe K. Proteinuria-reducing effects of tonsillectomy alone in IgA nephropathy recurring after kidney transplantation. Transplantation 2009; 88:935.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sato Y, Ishida H, Shimizu T, Tanabe K. Evaluation of tonsillectomy before kidney transplantation in patients with IgA nephropathy. Transpl Immunol 2014; 30:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Briganti EM, Russ GR, McNeil JJ, et al. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 2002; 347:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park S, Baek CH, Cho H, et al. Glomerular crescents are associated with worse graft outcome in allograft IgA nephropathy. Am J Transplant 2019; 19:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choy BY, Chan TM, Lo SK, et al. Renal transplantation in patients with primary immunoglobulin A nephropathy. Nephrol Dial Transplant 2003; 18:2399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sumethkul V, Jirasiritham S, Chalermsanyakorn P, Buranachokpaisan W. Chronic rejection: a significant predictor of poor outcome for recurrence IgA nephropathy. Transplant Proc 2001; 33:3375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kimata N, Tanabe K, Ishikawa N, et al. Correlation between proteinuria and prognosis of transplant IgA nephropathy. Transplant Proc 1996; 28:1537.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alachkar N, Delsante M, Greenberg RS, et al. Evaluation of the Modified Oxford Score in Recurrent IgA Nephropathy in North American Kidney Transplant Recipients: The Banff Recurrent Glomerulonephritis Working Group Report. Transplantation 2023; 107:2055.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lim BJ, Joo DJ, Kim MS, et al. Usefulness of Oxford classification in assessing immunoglobulin A nephropathy after transplantation. Transplantation 2013; 95:1491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park S, Go H, Baek CH, et al. Clinical importance of the updated Oxford classification in allograft IgA nephropathy. Am J Transplant 2019; 19:2855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDonald KJ, McMillan MA, Rodger RS, et al. Persistent dipstick haematuria following renal transplantation. Clin Transplant 2004; 18:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meulders Q, Pirson Y, Cosyns JP, et al. Course of Henoch-Schönlein nephritis after renal transplantation. Report on ten patients and review of the literature. Transplantation 1994; 58:1179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Han SS, Sun HK, Lee JP, et al. Outcome of renal allograft in patients with Henoch-Schönlein nephritis: single-center experience and systematic review. Transplantation 2010; 89:721.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thervet E, Aouizerate J, Noel LH, et al. Histologic recurrence of Henoch-Schonlein Purpura nephropathy after renal transplantation on routine allograft biopsy. Transplantation 2011; 92:907.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cronin CC, Feighery A, Ferriss JB, et al. High prevalence of celiac disease among patients with insulin-dependent (type I) diabetes mellitus. Am J Gastroenterol 1997; 92:2210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newell GC. Cirrhotic glomerulonephritis: incidence, morphology, clinical features, and pathogenesis. Am J Kidney Dis 1987; 9:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasternack A, Collin P, Mustonen J, et al. Glomerular IgA deposits in patients with celiac disease. Clin Nephrol 1990; 34:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amore A, Roccatello D, Picciotto G, et al. Processing of IgA aggregates in a rat model of chronic liver disease. Clin Immunol Immunopathol 1997; 84:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amore A, Coppo R, Roccatello D, et al. Experimental IgA nephropathy secondary to hepatocellular injury induced by dietary deficiencies and heavy alcohol intake. Lab Invest 1994; 70:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coppo R, Mazzucco G, Martina G, et al. Gluten-induced experimental IgA glomerulopathy. Lab Invest 1989; 60:499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghabra N, Piraino B, Greenberg A, Banner B. Resolution of cirrhotic glomerulonephritis following successful liver transplantation. Clin Nephrol 1991; 35:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woodrow G, Innes A, Boyd SM, Burden RP. A case of IgA nephropathy with coeliac disease responding to a gluten-free diet. Nephrol Dial Transplant 1993; 8:1382.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coppo R, Amore A, Roccatello D. Dietary antigens and primary immunoglobulin A nephropathy. J Am Soc Nephrol 1992; 2:S173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenberg HG, Martínez PS, Vaccarezza AS, Martínez LV. Morphological findings in 70 kidneys of living donors for renal transplant. Pathol Res Pract 1990; 186:619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suzuki K, Honda K, Tanabe K, et al. Incidence of latent mesangial IgA deposition in renal allograft donors in Japan. Kidney Int 2003; 63:2286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ji S, Liu M, Chen J, et al. The fate of glomerular mesangial IgA deposition in the donated kidney after allograft transplantation. Clin Transplant 2004; 18:536.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanfilippo F, Croker BP, Bollinger RR. Fate of four cadaveric donor renal allografts with mesangial IgA deposits. Transplantation 1982; 33:370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koselj M, Rott T, Vizjak A, Kveder R. IgA nephropathy as a donor-transmitted disease in renal transplant recipients. Transplant Proc 1991; 23:2643.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7344 Version 28.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15696457" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : IgA nephropathy with crescents in kidney transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16278579" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Exclusive characteristics of graft survival and risk factors in recipients with immunoglobulin A nephropathy: a retrospective analysis of registry data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16412967" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Considerations in retransplantation of the failed renal allograft recipient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16939521" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Recurrent glomerulonephritis after kidney transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34362788" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Recurrence of IgA Nephropathy after Kidney Transplantation in Adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8052439" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Recurrent mesangial IgA nephritis following renal transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11213065" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Live donor renal allograft in end-stage renal failure patients from immunoglobulin A nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8712229" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Recurrence of immunoglobulin A nephropathy after renal transplantation in the cyclosporine era.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9583865" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Single-center long-term results of renal transplantation for IgA nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9113449" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : The fate of renal transplants in patients with IgA nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23229925" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : The long-term outcome of renal transplantation of IgA nephropathy and the impact of recurrence on graft survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11961024" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Preemptive kidney transplantation: the advantage and the advantaged.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11236776" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Effect of the use or nonuse of long-term dialysis on the subsequent survival of renal transplants from living donors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12451234" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes: a paired donor kidney analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11703614" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Kidney transplantation in patients with IgA mesangial glomerulonephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10485372" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Clinical risk factors for recurrence of IgA nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11680657" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Favorable outcome of renal transplantation in patients with IgA nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11532693" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Recurrent IgA nephropathy in renal transplant allografts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17006322" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Recurrence of IgA nephropathy among renal allograft recipients from living donors is greater among those with zero HLA mismatches.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19761553" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Impact of recurrent disease and chronic allograft nephropathy on the long-term allograft outcome in patients with IgA nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3041801" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Recurrent IgA nephropathy in living-related donor transplantation: recurrence or transmission of familial disease?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9752688" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : [A clinicopathological study of recurrent IgA nephropathy following renal transplantation].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1713306" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Association of HLA-DQw4 with IgA nephropathy in the Japanese population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2314543" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : The role of HLA-DR4 in the long-term prognosis of IgA nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19674013" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : HLA-B8, DR3: a new risk factor for graft failure after renal transplantation in patients with underlying immunoglobulin A nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22167589" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : IgA nephropathy recurs early in the graft when assessed by protocol biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32187607" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : IgA Nephropathy Recurrence after Kidney Transplantation: Role of Recipient Age and Human Leukocyte Antigen-B Mismatch.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28926143" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Recurrence of IgA nephropathy after kidney transplantation in steroid continuation versus early steroid-withdrawal regimens: a retrospective analysis of the UNOS/OPTN database.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29345747" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Recurrent IgA nephropathy after renal transplantation and steroid withdrawal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3055960" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Recurrence of IgA nephropathy in renal allografts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28255003" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Prognostic Value of Serum Biomarkers of Autoimmunity for Recurrence of IgA Nephropathy after Kidney Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21399633" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Genome-wide association study identifies susceptibility loci for IgA nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25305756" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26825529" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Rare Variants in the Complement Factor H-Related Protein 5 Gene Contribute to Genetic Susceptibility to IgA Nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9074580" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Mycophenolate mofetil for systemic vasculitis and IgA nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10052478" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14678043" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Peritubular capillary changes and C4d deposits are associated with transplant glomerulopathy but not IgA nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15797890" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Recurrent IgA nephropathy after renal transplantation despite immunosuppressive regimens with mycophenolate mofetil.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22207327" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : The impact of mycophenolate mofetil versus azathioprine as adjunctive therapy to cyclosporine on the rates of renal allograft loss due to glomerular disease recurrence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19353768" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Impact of immunosuppressive medication on the risk of renal allograft failure due to recurrent glomerulonephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21797974" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Steroids and recurrent IgA nephropathy after kidney transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18497694" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Antithymocyte globulin (ATG) induction therapy and disease recurrence in renal transplant recipients with primary IgA nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17565315" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Alemtuzumab induction and recurrence of glomerular disease after kidney transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2325801" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Loss of renal graft due to recurrent IgA nephropathy with rapidly progressive course: an unusual clinical evolution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8107943" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Recurrent IgA nephropathy in a renal allograft presenting as crescentic glomerulonephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9392321" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Recurrent immunoglobulin A nephropathy after renal transplantation: a significant contributor to graft loss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10809812" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : A clinicopathological study of IgA nephropathy in renal transplant recipients: beneficial effect of angiotensin-converting enzyme inhibitor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16968729" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Does angiotensin blockade influence graft outcome in renal transplant recipients with IgA nephropathy?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12809474" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Fish oil therapy in recurrent IgA nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36270561" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37085262" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Targeted-release budesonide in recurrent IgA nephropathy after kidney transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27821627" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23941658" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Tonsillectomy ameliorates histological damage of recurrent immunoglobulin A nephropathy after kidney transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19935466" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Proteinuria-reducing effects of tonsillectomy alone in IgA nephropathy recurring after kidney transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24246415" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Evaluation of tonsillectomy before kidney transplantation in patients with IgA nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12110738" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Risk of renal allograft loss from recurrent glomerulonephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29718591" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Glomerular crescents are associated with worse graft outcome in allograft IgA nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14551373" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Renal transplantation in patients with primary immunoglobulin A nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11750443" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Chronic rejection: a significant predictor of poor outcome for recurrence IgA nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8658776" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Correlation between proteinuria and prognosis of transplant IgA nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37202854" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Evaluation of the Modified Oxford Score in Recurrent IgA Nephropathy in North American Kidney Transplant Recipients: The Banff Recurrent Glomerulonephritis Working Group Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23677050" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Usefulness of Oxford classification in assessing immunoglobulin A nephropathy after transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31017369" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Clinical importance of the updated Oxford classification in allograft IgA nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15142055" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Persistent dipstick haematuria following renal transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7992359" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Course of Henoch-Schönlein nephritis after renal transplantation. Report on ten patients and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20010329" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Outcome of renal allograft in patients with Henoch-Schönlein nephritis: single-center experience and systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21869738" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Histologic recurrence of Henoch-Schonlein Purpura nephropathy after renal transplantation on routine allograft biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9399754" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : High prevalence of celiac disease among patients with insulin-dependent (type I) diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3548338" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Cirrhotic glomerulonephritis: incidence, morphology, clinical features, and pathogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2225554" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Glomerular IgA deposits in patients with celiac disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9245540" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Processing of IgA aggregates in a rat model of chronic liver disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8302021" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Experimental IgA nephropathy secondary to hepatocellular injury induced by dietary deficiencies and heavy alcohol intake.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2709812" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Gluten-induced experimental IgA glomerulopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2007299" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Resolution of cirrhotic glomerulonephritis following successful liver transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8159309" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : A case of IgA nephropathy with coeliac disease responding to a gluten-free diet.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1600133" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Dietary antigens and primary immunoglobulin A nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2149595" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Morphological findings in 70 kidneys of living donors for renal transplant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12753320" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Incidence of latent mesangial IgA deposition in renal allograft donors in Japan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15344956" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : The fate of glomerular mesangial IgA deposition in the donated kidney after allograft transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7041362" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Fate of four cadaveric donor renal allografts with mesangial IgA deposits.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1926514" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : IgA nephropathy as a donor-transmitted disease in renal transplant recipients.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
